Investor Alert

Market Pulse Archives

April 16, 2020, 10:38 a.m. EDT

UroGen shares jump 10% on FDA approval of rare cancer treatment

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    UroGen Pharma Ltd. (URGN)
  • X
    SPDR S&P Biotech ETF (XBI)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of UroGen Pharma Ltd. /zigman2/quotes/202929873/composite URGN -1.27% gained 10.7% in premarket trading on Thursday after the Food and Drug Administration approved the company's urothelial cancer treatment the night before. The therapy, Jelmyto, allows patients to undergo treatment for this type of rare cancer without surgery, the company said. "This novel, minimally invasive, kidney-sparing treatment has the potential to transform the way low-grade upper tract urothelial cancer is treated," Dr. Seth Lerner, principal investigator of the treatment's Phase 3 trial, said in a news release. "We believe a non-surgical option such as Jelmyto is meaningfully differentiated," Stifel analysts told investors on Thursday, though they noted that it's still unclear how the company will approach a commercial launch strategy during the COVID-19 pandemic. UroGen's stock has tumbled 36.9% year-to-date, while the SPDR S&P Biotech Exchange-Traded Fund /zigman2/quotes/205950134/composite XBI -1.02% is down 11.2%.

US : U.S.: Nasdaq
$ 23.35
-0.30 -1.27%
Volume: 110,443
July 10, 2020 4:00p
P/E Ratio
Dividend Yield
Market Cap
$512.19 million
Rev. per Employee
US : U.S.: NYSE Arca
$ 114.92
-1.18 -1.02%
Volume: 3.11M
July 10, 2020 4:00p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.